Xi Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xi Chen has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Hao-Yang Huang
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China
15 shared publications- Jia-Yu Zhou
Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China
15 shared publications - Liang-Ru Ke
Department of Medical Imaging, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China
15 shared publications - Xun Cao
Department of Critical Care Medicine, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China
15 shared publications - Lin-Quan Tang
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
14 shared publications - Lu-Jun Han
Department of Radiology, Sun Yat-Sen University Cancer Centre, Guangzhou, China
14 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Cell Death Discovery
SRPX2 aggravates tumor progression and immune resistance through TGFBR2-mediated epithelial–mesenchymal transition in colorectal cancer
Colorectal cancer (CRC) metastasis presents a formidable clinical challenge, particularly for microsatellite stability (MSS) subtypes that show limited response to current targeted therapies and immunotherapies. While transforming growth factor beta (TGF-β) signaling is recognized as an inducer of the mesenchymal transition program, including epithelial–mesenchymal transition (EMT) and extracellular matrix (ECM) remodeling in metastatic progression, the upstream molecular mechanisms controlling TGF-β pathway activation in metastasis remain unclear. Here, we identified sushi repeat-containing protein X-linked 2 (SRPX2) as a novel metastasis driver that orchestrates TGF-β signaling through an unexpected molecular mechanism. Our multi-omics analysis of metastatic CRC datasets revealed SRPX2 as the top candidate gene associated with aggressive progression and immunotherapy resistance. Mechanistically, SRPX2 binds to and stabilizes TGFBR2, activating the TGF-β signaling pathway that promotes EMT/ECM reprogramming. We further demonstrated that SRPX2 ablation suppresses liver metastasis and enhances tumor sensitivity to immune checkpoint inhibitors, accompanied by reduced mesenchymal abundance. These findings establish SRPX2 as a crucial molecular switch controlling TGF-β pathway activation in CRC metastasis and reveal its dual role in promoting stromal remodeling and immune evasion. Our work provides a compelling rationale for targeting the SRPX2/TGF-β axis as a novel therapeutic strategy for aggressive CRC subsets.
- 15 October 2026
- Published by Springer Nature in Cell Death Discovery
Open AccessSRPX2 aggravates tumor progression and immune resistance through TGFBR2-mediated epithelial–mesenchymal transition in colorectal cancer
Colorectal cancer (CRC) metastasis presents a formidable clinical challenge, particularly for microsatellite stability (MSS) subtypes that show limited response to current targeted therapies and immunotherapies. While transforming growth factor beta (TGF-β) signaling is recognized as an inducer of the mesenchymal transition program, including epithelial–mesenchymal transition (EMT) and extracellular matrix (ECM) remodeling in metastatic progression, the upstream molecular mechanisms controlling TGF-β pathway activation in metastasis remain unclear. Here, we identified sushi repeat-containing protein X-linked 2 (SRPX2) as a novel metastasis driver that orchestrates TGF-β signaling through an unexpected molecular mechanism. Our multi-omics analysis of metastatic CRC datasets revealed SRPX2 as the top candidate gene associated with aggressive progression and immunotherapy resistance. Mechanistically, SRPX2 binds to and stabilizes TGFBR2, activating the TGF-β signaling pathway that promotes EMT/ECM reprogramming. We further demonstrated that SRPX2 ablation suppresses liver metastasis and enhances tumor sensitivity to immune checkpoint inhibitors, accompanied by reduced mesenchymal abundance. These findings establish SRPX2 as a crucial molecular switch controlling TGF-β pathway activation in CRC metastasis and reveal its dual role in promoting stromal remodeling and immune evasion. Our work provides a compelling rationale for targeting the SRPX2/TGF-β axis as a novel therapeutic strategy for aggressive CRC subsets.
- 28 May 2026
- Published by Springer Nature in Pharmacological Reports
- Vol. 78 (4) , 1-14
Association between elemental concentrations and chemotherapy-related acute adverse events in patients with nasopharyngeal carcinoma
Background While environmental exposure to toxic elements, such as cadmium (Cd) and chromium (Cr), is known to impair general organ function, its specific impact on patients’ tolerance to platinum (Pt)-based chemotherapy remains largely unexplored. This study aimed to determine whether pretreatment accumulation of specific trace elements is associated with the occurrence of acute adverse events (AEs) in patients with nasopharyngeal carcinoma (NPC) receiving platinum (Pt)-based chemotherapy. Methods A single-center, prospective, longitudinal study was conducted on 140 patients with NPC. Elemental concentrations measured before the initiation of chemotherapy (hereafter referred to as “pretreatment concentrations”) of 13 elements (arsenic (As), calcium (Ca), Cd, cobalt (Co), Cr, copper (Cu), mercury (Hg), magnesium (Mg), nickel (Ni), lead (Pb), platinum (Pt), selenium (Se), and zinc (Zn)) and acute AEs for each chemotherapy cycle were recorded. Elemental concentrations were measured in blood (B) and urine (U) using inductively coupled plasma mass spectrometry (ICP-MS). Univariate and multivariate logistic regression analyses were performed to evaluate the associations between element levels and chemotherapy-related acute adverse events (AEs). Results The study enrolled 140 patients with stage II (n = 2, 1.4%), III (n = 76, 54.3%), and IVA (n = 62, 44.3%) NPC. Moderate positive correlations (Spearman’s correlation coefficients ranging from 0.2 to 0.7, p < 0.05) were observed between the concentrations of individual elements (such as Cd, Pb, and Cr) measured in paired whole blood and urine samples. NPC patients with high urinary Cr, blood Cd, and urinary Pb concentrations were more likely to experience higher incidences of thrombocytopenia (5% vs. 23%, p = 0.002), hepatotoxicity (40% vs. 60%, p = 0.028), and dysglycemia (46% vs. 74%, p < 0.001), respectively. In the multivariate adjusted logistic regression, blood Cd (OR = 3.65, 95% CI 1.38–9.64; p = 0.009) and urinary Cr (OR = 3.34, 95% CI 1.60–19.87; p = 0.007) were identified as independent predictors of hepatotoxicity and thrombocytopenia in NPC patients receiving Pt-based chemotherapy. Conclusions Pretreatment elevation of specific elements, particularly blood Cd and urinary Cr, was independently associated with a significantly increased risk of chemotherapy-related acute AEs. Specifically, blood Cd and urinary Cr were independent predictors of hepatotoxicity and thrombocytopenia in NPC patients undergoing Pt-based chemotherapy.
- 28 May 2026
- Published by Springer Nature in Pharmacological Reports
- Vol. 78 (4) , 1-14
Association between elemental concentrations and chemotherapy-related acute adverse events in patients with nasopharyngeal carcinoma
Background While environmental exposure to toxic elements, such as cadmium (Cd) and chromium (Cr), is known to impair general organ function, its specific impact on patients’ tolerance to platinum (Pt)-based chemotherapy remains largely unexplored. This study aimed to determine whether pretreatment accumulation of specific trace elements is associated with the occurrence of acute adverse events (AEs) in patients with nasopharyngeal carcinoma (NPC) receiving platinum (Pt)-based chemotherapy. Methods A single-center, prospective, longitudinal study was conducted on 140 patients with NPC. Elemental concentrations measured before the initiation of chemotherapy (hereafter referred to as “pretreatment concentrations”) of 13 elements (arsenic (As), calcium (Ca), Cd, cobalt (Co), Cr, copper (Cu), mercury (Hg), magnesium (Mg), nickel (Ni), lead (Pb), platinum (Pt), selenium (Se), and zinc (Zn)) and acute AEs for each chemotherapy cycle were recorded. Elemental concentrations were measured in blood (B) and urine (U) using inductively coupled plasma mass spectrometry (ICP-MS). Univariate and multivariate logistic regression analyses were performed to evaluate the associations between element levels and chemotherapy-related acute adverse events (AEs). Results The study enrolled 140 patients with stage II (n = 2, 1.4%), III (n = 76, 54.3%), and IVA (n = 62, 44.3%) NPC. Moderate positive correlations (Spearman’s correlation coefficients ranging from 0.2 to 0.7, p < 0.05) were observed between the concentrations of individual elements (such as Cd, Pb, and Cr) measured in paired whole blood and urine samples. NPC patients with high urinary Cr, blood Cd, and urinary Pb concentrations were more likely to experience higher incidences of thrombocytopenia (5% vs. 23%, p = 0.002), hepatotoxicity (40% vs. 60%, p = 0.028), and dysglycemia (46% vs. 74%, p < 0.001), respectively. In the multivariate adjusted logistic regression, blood Cd (OR = 3.65, 95% CI 1.38–9.64; p = 0.009) and urinary Cr (OR = 3.34, 95% CI 1.60–19.87; p = 0.007) were identified as independent predictors of hepatotoxicity and thrombocytopenia in NPC patients receiving Pt-based chemotherapy. Conclusions Pretreatment elevation of specific elements, particularly blood Cd and urinary Cr, was independently associated with a significantly increased risk of chemotherapy-related acute AEs. Specifically, blood Cd and urinary Cr were independent predictors of hepatotoxicity and thrombocytopenia in NPC patients undergoing Pt-based chemotherapy.
- Open Access
- 10 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial
In nasopharyngeal carcinoma, cisplatin is known to be associated with poor treatment compliance and notable side effects. More effective and safer platinum drugs are needed for the treatment of patients with nasopharyngeal carcinoma. In 2021, our multicenter, randomized, phase 3 trial reported that lobaplatin and fluorouracil induction chemotherapy plus concurrent chemoradiotherapy resulted in non-inferior survival and fewer toxic effects than did cisplatin-based therapy in nasopharyngeal carcinoma. Data from the 10-year survival analysis are updated here. With a median follow-up of 10.6 years in the intention-to-treat population, 10-year progression-free survival is 70.7% in the lobaplatin-based therapy group vs. 71.9% in the cisplatin-based therapy group (HR 1.02, 95% CI 0.72–1.43; log-rank p = 0.885). The difference between the groups is 1.2% (95% CI −6.7–9.1, pnon-inferiority = 0.015), which is lower than the prespecified non-inferiority margin of 10%. The results are similar when we analyze patients in the per-protocol population. In the univariable and multivariable analyses, stage is an independent prognostic factor for progression-free survival (p = 0.001). The subgroup analyses suggest that the non-inferiority of lobaplatin-based therapy did not differ among specific populations. The incidence of late toxic effects is similar between the therapy groups, except for grades 1–2 peripheral neuropathy (p = 0.033), grades 1–2 deafness/otitis (p = 0.021), and grades 1–2/3 nephrotoxicity (p = 0.005; p = 0.021), the incidence of which is greater in the cisplatin-based therapy group than in the lobaplatin-based therapy group. Our findings suggest that lobaplatin and fluorouracil induction chemotherapy plus lobaplatin-based concurrent chemoradiotherapy is an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
- 10 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessFinal survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial
In nasopharyngeal carcinoma, cisplatin is known to be associated with poor treatment compliance and notable side effects. More effective and safer platinum drugs are needed for the treatment of patients with nasopharyngeal carcinoma. In 2021, our multicenter, randomized, phase 3 trial reported that lobaplatin and fluorouracil induction chemotherapy plus concurrent chemoradiotherapy resulted in non-inferior survival and fewer toxic effects than did cisplatin-based therapy in nasopharyngeal carcinoma. Data from the 10-year survival analysis are updated here. With a median follow-up of 10.6 years in the intention-to-treat population, 10-year progression-free survival is 70.7% in the lobaplatin-based therapy group vs. 71.9% in the cisplatin-based therapy group (HR 1.02, 95% CI 0.72–1.43; log-rank p = 0.885). The difference between the groups is 1.2% (95% CI −6.7–9.1, pnon-inferiority = 0.015), which is lower than the prespecified non-inferiority margin of 10%. The results are similar when we analyze patients in the per-protocol population. In the univariable and multivariable analyses, stage is an independent prognostic factor for progression-free survival (p = 0.001). The subgroup analyses suggest that the non-inferiority of lobaplatin-based therapy did not differ among specific populations. The incidence of late toxic effects is similar between the therapy groups, except for grades 1–2 peripheral neuropathy (p = 0.033), grades 1–2 deafness/otitis (p = 0.021), and grades 1–2/3 nephrotoxicity (p = 0.005; p = 0.021), the incidence of which is greater in the cisplatin-based therapy group than in the lobaplatin-based therapy group. Our findings suggest that lobaplatin and fluorouracil induction chemotherapy plus lobaplatin-based concurrent chemoradiotherapy is an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Figure 1. Kaplan-Meier analyses of the efficacy population.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Figure 1. Kaplan-Meier analyses of the efficacy population.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 4. Summary of diagnosis of residual nasopharyngeal carcinoma.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 4. Summary of diagnosis of residual nasopharyngeal carcinoma.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Purpose:Patients with residual nasopharyngeal carcinoma after receiving standard-of-care treatment have poor prognoses. In this trial, we aimed to assess the efficacy and safety of capecitabine maintenance therapy in patients with residual nasopharyngeal carcinoma.Patients and Methods:This open-label, single-arm, phase II trial was conducted at Sun Yat-sen University Cancer Center. We recruited patients of 18 to 70 years of age with an Eastern Cooperative Oncology Group performance status score of 0 to 1, histopathologically or cytologically confirmed nasopharyngeal carcinoma (without distant metastasis), who had residual disease after receiving definitive treatment. Patients received 1 year of capecitabine maintenance therapy. The primary endpoint was 2-year progression-free survival.Results:Between January 1, 2019, and December 30, 2022, 111 patients were recruited and commenced capecitabine maintenance therapy for 1 year. After a median follow-up duration of 34.8 months (IQR = 30.5–45.2), progression-free survival was 92% at 1 year, 86% at 2 years, and 81% at 3 years. Adverse events were reported in 97.3% of patients. Hand-foot syndrome was the most common adverse event (59.5%). In addition, 28.7% of patients experienced grade 3 treatment-related adverse events, the most common of which was hand-foot syndrome (7.2%); no grade 4 or 5 adverse events were recorded. A total of 72.1% of patients received the full dosage of capecitabine, and 76.6% of patients completed the 1-year capecitabine maintenance therapy.Conclusions:The antitumor efficacy of capecitabine maintenance therapy is promising, and the safety profile is manageable in patients with residual nasopharyngeal carcinoma after receiving standard-of-care treatment.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Purpose:Patients with residual nasopharyngeal carcinoma after receiving standard-of-care treatment have poor prognoses. In this trial, we aimed to assess the efficacy and safety of capecitabine maintenance therapy in patients with residual nasopharyngeal carcinoma.Patients and Methods:This open-label, single-arm, phase II trial was conducted at Sun Yat-sen University Cancer Center. We recruited patients of 18 to 70 years of age with an Eastern Cooperative Oncology Group performance status score of 0 to 1, histopathologically or cytologically confirmed nasopharyngeal carcinoma (without distant metastasis), who had residual disease after receiving definitive treatment. Patients received 1 year of capecitabine maintenance therapy. The primary endpoint was 2-year progression-free survival.Results:Between January 1, 2019, and December 30, 2022, 111 patients were recruited and commenced capecitabine maintenance therapy for 1 year. After a median follow-up duration of 34.8 months (IQR = 30.5–45.2), progression-free survival was 92% at 1 year, 86% at 2 years, and 81% at 3 years. Adverse events were reported in 97.3% of patients. Hand-foot syndrome was the most common adverse event (59.5%). In addition, 28.7% of patients experienced grade 3 treatment-related adverse events, the most common of which was hand-foot syndrome (7.2%); no grade 4 or 5 adverse events were recorded. A total of 72.1% of patients received the full dosage of capecitabine, and 76.6% of patients completed the 1-year capecitabine maintenance therapy.Conclusions:The antitumor efficacy of capecitabine maintenance therapy is promising, and the safety profile is manageable in patients with residual nasopharyngeal carcinoma after receiving standard-of-care treatment.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 3. Administration of concurrent chemoradiotherapy.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 3. Administration of concurrent chemoradiotherapy.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 7. Subsequent treatments of patients who did experienced disease progression events.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 7. Subsequent treatments of patients who did experienced disease progression events.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 2. Administration of upfront induction chemotherapy.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 2. Administration of upfront induction chemotherapy.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 1. Location of residual nasopharyngeal carcinoma.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 1. Location of residual nasopharyngeal carcinoma.